These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32382482)

  • 1. Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer.
    Jia Q; Chiu L; Wu S; Bai J; Peng L; Zheng L; Zang R; Li X; Yuan B; Gao Y; Wu D; Li X; Wu L; Sun J; He J; Robinson BWS; Zhu B
    Adv Sci (Weinh); 2020 May; 7(9):1903410. PubMed ID: 32382482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer.
    Su C; Wang X; Zhou J; Zhao J; Zhou F; Zhao G; Xu X; Zou X; Zhu B; Jia Q
    Transl Lung Cancer Res; 2021 Mar; 10(3):1256-1265. PubMed ID: 33889507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.
    Liang H; Xu Y; Chen M; Zhao J; Zhong W; Liu X; Gao X; Li S; Li J; Guo C; Jia H; Wang M
    Front Immunol; 2021; 12():749461. PubMed ID: 35356154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
    Okada M; Shimizu K; Fujii SI
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.
    Hwang M; Canzoniero JV; Rosner S; Zhang G; White JR; Belcaid Z; Cherry C; Balan A; Pereira G; Curry A; Niknafs N; Zhang J; Smith KN; Sivapalan L; Chaft JE; Reuss JE; Marrone K; Murray JC; Li QK; Lam V; Levy BP; Hann C; Velculescu VE; Brahmer JR; Forde PM; Seiwert T; Anagnostou V
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
    Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
    Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
    Anderson CJ; Yang H; Parsons J; Ahrens WA; Jagosky MH; Hsu JH; Patt JC; Kneisl JS; Steuerwald NM
    Clin Orthop Relat Res; 2024 Jun; ():. PubMed ID: 38905450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
    Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
    Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Forde PM; White JR; Niknafs N; Hruban C; Naidoo J; Marrone K; Sivakumar IKA; Bruhm DC; Rosner S; Phallen J; Leal A; Adleff V; Smith KN; Cottrell TR; Rhymee L; Palsgrove DN; Hann CL; Levy B; Feliciano J; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Isbell JM; Sauter JL; Taube J; Scharpf RB; Karchin R; Pardoll DM; Chaft JE; Hellmann MD; Brahmer JR; Velculescu VE
    Cancer Res; 2019 Mar; 79(6):1214-1225. PubMed ID: 30541742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized immunotherapy in cancer precision medicine.
    Kiyotani K; Toyoshima Y; Nakamura Y
    Cancer Biol Med; 2021 Aug; 18(4):955-65. PubMed ID: 34369137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
    Li J; Jiang W; Wei J; Zhang J; Cai L; Luo M; Wang Z; Sun W; Wang S; Wang C; Dai C; Liu J; Wang G; Wang J; Xu Q; Deng Y
    J Transl Med; 2020 Aug; 18(1):293. PubMed ID: 32738923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigens: promising targets for cancer therapy.
    Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
    Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy: current technology and clinical applications.
    Nikanjam M; Kato S; Kurzrock R
    J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
    Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
    Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.